Wechselwirkungen · Emend
EMEND 125 mg hard capsules EMEND 80 mg hard capsules · Abschnitt 4.5 · PDF-Seite 6
HOS-112526 · Präparat HOS-093697
Induction As a mild inducer of CYP2C9, CYP3A4 and glucuronidation, aprepitant can decrease plasma concentrations of substrates eliminated by these routes within two weeks following initiation and treatment. This effect may become apparent only after the end of a 3-day treatment with EMEND. For CYP2C9 and CYP3A4 substrates, the induction is transient with a maximum effect reached 3-5 days after end of the EMEND 3-day treatment. The effect is maintained for a few days, thereafter slowly declines and is clinically insignificant by two weeks after end of EMEND treatment. Mild induction of glucuronidation is also seen with 80 mg oral aprepitant given for 7 days. Data are lacking regarding effects on CYP2C8 and CYP2C19. Caution is advised when warfarin, acenocoumarol, tolbutamide, phenytoin or other active substances that are known to be metabolised by CYP2C9 are administered during this time period.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) tolbutamide (HOS-086568)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-24T11:24:00Z · SHA-256 afd6062a51e59b36e448c9117685894e4529fcde2f5e673f4401f91bb32d7081 · Passage 06b9369c697bb573f6c8dcd6de97a932ec90843bd807852c1a1204fb206868b6 · Zeichen 6274–7181 im Abschnitt